Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ford Motor Company — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.34 (market cap $505.73M), while Ford Motor Company trades at $13.85 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 110.2× Ginkgo Bioworks Holdings Inc's market cap, and Ford Motor Company pays a 4.29% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | F | |
|---|---|---|
Market Cap | $505.73M | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $17.44 |
52-Week Low | $5.48 | $11.21 |
Enterprise Value | $607.68M | $187.71B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Ford (F) trades at $13.86, down 1.14%, with a bearish technical signal. Recent earnings show volatility, with Q1 and Q2 2026 beats but a Q4 2025 miss. The company reported a net loss of $8.18B for 2025, though operating cash flow remains strong at $21.28B. News highlights the upcoming affordable Fathom EV truck priced at $28,350, targeting market share gains amid high vehicle prices.
The outlook is mixed: analyst consensus is a Buy with a $16.18 target, offering potential upside, but risks include intense EV competition, profitability challenges, and high debt levels. The stock's low P/E of 11.84 may attract value investors, but execution on new models is critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
